BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia

  April 27, 2026

   · 

  5 min read
• Press Releases

  Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

  April 27, 2026

   · 

  4 min read
• Press Releases

  Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

  April 27, 2026

   · 

  6 min read
• Press Releases

  Microbix Product Results Being Presented at 2026 PASCV

  April 27, 2026

   · 

  5 min read
• Press Releases

  Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma

  April 27, 2026

   · 

  14 min read
• Press Releases

  Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

  April 27, 2026

   · 

  10 min read
• Press Releases

  Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

  April 27, 2026

   · 

  6 min read
• Press Releases

  Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

  April 27, 2026

   · 

  6 min read
• Press Releases

  Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

  April 27, 2026

   · 

  9 min read
• Press Releases

  Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

  April 27, 2026

   · 

  5 min read